-
September 7, 2022 Psychedelic Stocks: ARK Invest and the Reverse Midas TouchCathie Wood is buying up stocks from the most dubious actors in the psychedelic sector....
-
August 19, 2022 Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine CollapsesThe psychedelic renaissance hits a rough patch as major companies look to tighten their belts...
-
August 15, 2022 MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts PipelineMindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is...
-
August 11, 2022 An Inside Look into Field Trip’s Next-Generation Psychedelic, FT-104Field Trip is the only company exploring the therapeutic potential of a 4-HO-DiPT prodrug called...
-
August 10, 2022 Compass Pathways Sued for Stealing Trade SecretsCompass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual...
-
July 29, 2022 The Real Reason Cybin Bought Entheon’s DMT Clinical TrialIn a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical....
-
July 28, 2022 Project Solace: The World’s Largest Medical Psilocybin Access and Data ProjectProject Solace uses real-world data to inform development of regulated psilocybin therapy, led by Canadian...
-
July 27, 2022 3 Microdosing Clinical Trials to Keep an Eye OnDoes microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical...
-
July 22, 2022 A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new...
-
July 22, 2022 Company Spotlight: NaturoMed TherapeuticsCanadian organic mushroom company NaturoMed Therapeutics looks to produce psilocybin in Q4 2022
